JP2011217671A - Method for producing useful substance - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a culture method for maintaining secretory production of bacteria in a method of secretory production of a useful substance using a surfactant.SOLUTION: In a method for extracellular secretory production of a useful substance comprising the following steps (a) and (b), where a Kjeldahl nitrogen amount in the culture solution in the step (a) is 15-500 g/L during a time of ≥10% time required for the step (a): the step (a) for extracellularly secreting a useful substance in the simultaneous existence of a culture solution for culturing useful substance producing bacteria and a surfactant (B), and the step (b) for separating from the bacteria the useful substance and the culture solution.

Description

  The present invention relates to a method for producing a useful substance. Specifically, the present invention relates to a method for producing a useful substance that secretes and produces a useful substance by causing a surfactant and bacteria to exist simultaneously.

Bacteria are widely used for producing useful substances such as amino acids and proteins. Escherichia coli is widely used as a bacterium for the production of useful substances. Along with the advancement of genetic engineering technology, we know the technology for efficiently producing useful proteins by introducing genes of proteins useful in medicine and industry into E. coli. It has been.
Usually, when protein is expressed using Escherichia coli, physical disruption methods such as ultrasonic waves, high-pressure homogenizers, and French presses are used to extract the target protein. However, these physical disruption methods have a problem that purity is lowered because a large amount of substances other than the target protein present in the cells of E. coli are mixed when the protein is extracted.
As a method for producing a useful substance that solves this problem, a method for secreting and producing a useful substance is known. Secretion production of a useful substance is effective both for the purpose of obtaining the target useful substance with high purity and for achieving high productivity.

In secretory production of useful substances, a method using a surfactant is known. For example, in the production of glutamic acid, polyoxyethylene sorbitan monopalmitate, which is a kind of surfactant, is used (Patent Document 1). A surfactant is also used in the production of proteins such as cellulase (Non-patent Document 1).
When secretory production is performed, high productivity can be maintained, and a longer production time leads to improved productivity. However, the factors necessary to sustain high productivity are not known.

International Publication No. 99/07853 Pamphlet

Bioindustry Association Fermentation and Metabolism Study Group, “Fermentation Handbook”, Kyoritsu Shuppan, July 2001, page 253

  The problem to be solved by the present invention is to provide a culture method for sustaining bacterial secretory production in a high state in a secretory production method of useful substances using a surfactant.

The inventors of the present invention have reached the present invention as a result of studies to achieve the above object.
That is, the present invention is a method for extracellular secretion production of a useful substance comprising the following steps (a) and (b), wherein the time in step (a) is 10% or more of the time required for step (a): The useful substance manufacturing method whose protein concentration in a culture solution is 15-500 g / L.
Step (a): A step of causing a useful substance to be secreted outside the cell by simultaneously presenting a culture solution for cultivating bacteria producing the useful substance and the surfactant (B).
Step (b): A step of separating bacteria from the culture solution and useful substances.

The present invention has the following effects.
By using the culture method of the present invention in the secretory production process of a useful substance using a surfactant, the production amount of the useful substance can be increased.

  Examples of bacteria in the present invention are given below, but are not limited thereto. Bacteria include eubacteria and archaea. Eubacteria include gram negative bacteria and gram positive bacteria. Gram-negative bacteria include Escherichia, Thermus, Rhizobium, Pseudomonas, Shewanella, Vibromo, Vibromo, Vibromo Examples include Salmonella, Acetobacter genus, Synechocystis genus, and the like. Gram-positive bacteria include the genus Bacillus (genus Bacillus), the genus Streptomyces (genus Streptomyces), the genus Corynebacterium (genus Corynebacterium), the genus Brevibacillus, the genus Bifidobacterium, and the genus Bifidobacterium. Examples include the genus Coccus (genus Lactococcus), the genus Enterococcus (genus Enterococcus), the genus Pediococcus (genus Pediococcus), the genus Leuconostoc (genus Leuconostoc), and the genus Streptomyces. Moreover, the bacterium to be used may have a specific gene deletion or gene overexpression.

  Among these, Escherichia bacteria are preferable from the viewpoint of productivity of useful substances, and Escherichia coli is more preferable.

  Useful substances in the present invention are not particularly limited, but include recombinant proteins (enzymes, hormone proteins, antibodies, peptides, etc.), oligosaccharides, nucleic acids, and the like.

  Recombinant proteins include enzymes (oxidoreductases (cholesterol oxidase, glucose oxidase, ascorbate oxidase, peroxidase, etc.), hydrolases (lysozyme, protease, serine protease, alkaline protease, amylase, lipase, cellulase, glucoamylase, etc.), Isomerase (such as glucose isomerase), transferase (such as acyltransferase and sulfotransferase), synthase (such as fatty acid synthase, phosphate synthase, and citrate synthase) and elimination enzyme (such as pectin lyase)}, hormone protein { Bone morphogenetic factor (BMP), interferon α, interferon β, interleukin 1-12, growth hormone, erythropoietin, insulin, granular Colony stimulating factor (G-CSF), tissue plasminogen activator (TPA), natriuretic peptide, blood coagulation factor VIII, somatomedin, glucagon, growth hormone releasing factor, serum albumin and calcitonin}, antibody {1 Chain antibody, IgG large subunit, IgG small subunit, etc.}, antigen protein {hepatitis B surface antigen, etc.}, functional protein {pronectin (registered trademark), etc.}, fluorescent protein (GFP, etc.), photoprotein (Lucherase, etc.) ) And the like. The peptide is not particularly limited in amino acid composition, and examples thereof include dipeptides and tripeptides.

  Examples of the oligosaccharide include sucrose, lactose, trehalose, maltose, raffinose, panose, cyclodextrin, galactooligosaccharide and fructooligosaccharide.

  Examples of nucleic acids include inosine monophosphate, adenosine monophosphate, guanosine monophosphate, and the like.

  Among these useful substances, peptides and proteins are preferable from the viewpoint of productivity of useful substances, more preferably recombinant proteins, and further preferably enzymes, single chain antibodies, hormone proteins, and antigen proteins.

  In the present invention, the surfactant (B) includes an amphoteric surfactant (B1), an anionic surfactant (B2), a nonionic surfactant (B3), and a cationic surfactant (B4).

  Examples of the amphoteric surfactant (B1) include a carboxylate amphoteric surfactant (B1-1), a sulfate ester amphoteric surfactant (B1-2), and a sulfonate amphoteric surfactant (B1-3). ) And phosphate ester type amphoteric surfactant (B1-4).

Carboxylate type amphoteric surfactant (B1-1) includes amino acid type amphoteric surfactant (B1-1-1), betaine type amphoteric surfactant (B1-1-2), and imidazoline type amphoteric surfactant ( B1-1-3) and the like.
The amino acid type amphoteric surfactant (B1-1-1) is an amphoteric surfactant having an amino group and a carboxyl group in the molecule, and examples thereof include a compound represented by the following general formula (1).
[R—NH— (CH ₂ ) _n —COO] _m M (1)
In general formula (1), R is a C1-C20 monovalent hydrocarbon group. n is an integer of 1 or 2. m is an integer of 1 or 2. M is a monovalent or divalent cation such as a hydrogen atom, an alkali metal, an alkaline earth metal, ammonium (including cations derived from amines and alkanolamines), and quaternary ammonium.
Further, (B1-1-1) is an alkylaminopropionic acid type amphoteric surfactant (such as sodium cocaminopropionate, sodium stearylaminopropionate and sodium laurylaminopropionate); an alkylaminoacetic acid type amphoteric surfactant ( And sodium N-lauroyl-N′-carboxymethyl-N′-hydroxyethylethylenediamine and the like.

The betaine-type amphoteric surfactant (B1-1-2) is an amphoteric surfactant having a quaternary ammonium salt-type cation moiety and a carboxylic acid-type anion moiety in the molecule. ) Alkyldimethylbetaines (stearyl dimethylaminoacetic acid betaine and lauryldimethylaminoacetic acid betaine etc.), amide betaines (coconut oil fatty acid amidopropyl betaine and lauric acid amidopropyl betaine etc.) and alkyldihydroxyalkyl betaines (lauryl dihydroxy) Ethyl betaine, etc.).
RN ⁺ (CH ₃ ) ₂ —CH ₂ COO ⁻ (2)
In general formula (2), R is a C1-C20 monovalent hydrocarbon group.

  Examples of the imidazoline-type amphoteric surfactant (B1-1-3) include 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine.

  Other amphoteric surfactants include glycine-type amphoteric surfactants such as sodium lauroyl glycine, sodium lauryl diaminoethyl glycine, lauryl diaminoethyl glycine hydrochloride and dioctyl diaminoethyl glycine hydrochloride; sulfobetaine types such as pentadecyl sulfotaurine Amphoteric surfactants; Coleamidopropyldimethylammoniopropanesulfonic acid (CHAPS), Coleamidopropyldimethylammonio 2-hydroxypropanesulfonic acid (CHAPSO); Alkylamine oxide amphoteric surfactants such as lauryldimethylamine oxide included.

  Examples of the anionic surfactant (B2) include ether carboxylic acid (B2-1) and its salt, sulfate ester (B2-2) or its salt, ether sulfate ester (B2-3) and its salt, sulfonate ( B2-4), sulfosuccinate (B2-5), phosphate ester (B2-6) and salt thereof, ether phosphate ester (B2-7) and salt thereof, fatty acid salt (B2-8), acylated amino acid Examples thereof include salts and naturally-derived carboxylic acids and salts thereof (such as chenodeoxycholic acid, cholic acid, and deoxycholic acid).

  The ether carboxylic acid (B2-1) or a salt thereof includes an ether carboxylic acid having a hydrocarbon group having 8 to 24 carbon atoms and a salt thereof, polyoxyethylene lauryl ether acetic acid, polyoxyethylene lauryl ether acetic acid sodium salt, Examples include sodium polyoxyethylene tridecyl ether acetate, sodium polyoxyethylene octyl ether acetate, and sodium lauryl glycol acetate.

  Examples of the sulfate ester (B2-2) and salts thereof include sulfate esters having a hydrocarbon group having 8 to 24 carbon atoms and salts thereof, such as sodium lauryl sulfate and triethanolamine salt of lauryl sulfate.

  Ether sulfate (B2-3) and salts thereof include ether sulfates having a hydrocarbon group having 8 to 24 carbon atoms and salts thereof, polyoxyethylene lauryl ether sulfate sodium salt and polyoxyethylene lauryl ether sulfate. A triethanolamine salt etc. are mentioned.

  Examples of the sulfonate (B2-4) include sodium dodecyl diphenyl ether disulfonate, sodium dodecylbenzene sulfonate, and sodium naphthalene sulfonate.

  Examples of the sulfosuccinate (B2-5) include polyoxyethylene lauryl sulfosuccinic acid disodium salt, sulfosuccinic acid lauryl disodium salt, and sulfosuccinic acid polyoxyethylene lauroyl ethanolamide disodium salt.

  Examples of the phosphate ester (B2-6) include octyl phosphate disodium salt and lauryl phosphate disodium salt.

  Examples of the ether phosphate (B2-7) include polyoxyethylene octyl ether phosphate disodium salt and polyoxyethylene lauryl ether phosphate disodium salt.

  Examples of the fatty acid salt (B2-8) include sodium octylate, sodium laurate, and sodium stearate.

  Nonionic surfactants (B3) include higher alcohol alkylene oxide (hereinafter abbreviated as AO) adduct (B3-1), alkylphenol AO adduct (B3-2), fatty acid AO adduct (B3-3) and Polyhydric alcohol type nonionic surfactant (B3-4) etc. are contained.

  The higher alcohol AO adduct (B3-1) includes polyoxyalkylene alkyl ethers and higher alcohols having 8 to 24 alkyl ether carbon atoms (decyl alcohol, dodecyl alcohol, coconut oil alkyl alcohol, octadecyl alcohol, oleyl alcohol, etc. ) Ethylene oxide (hereinafter abbreviated as EO) 1-20 mol and / or propylene oxide (hereinafter abbreviated as PO) 1-20 mol adduct (including block adducts and / or random adducts, etc.), etc. Is mentioned.

  The alkylphenol AO adduct (B3-2) includes an AO adduct of an alkylphenol having an alkyl group having 6 to 24 carbon atoms, an EO1 to 20 mol and / or PO1 to 20 mol adduct of octylphenol, and an EO1 of nonylphenol. -20 mol and / or PO 1-20 mol adducts and the like. Moreover, TRITON (registered trademark) X-114, igepal (registered trademark) CA-520, igepal (registered trademark) CA-630, and the like can be easily obtained from the market.

  As fatty acid AO adduct (B3-3), EO 1-20 mol of fatty acids having 8 to 24 carbon atoms (decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, coconut oil fatty acid, etc.) and / or Or PO1-20 mol adduct is contained, An oleic acid EO9 mol adduct, a dioleic acid EO12 mol adduct, a dioleic acid EO20 mol adduct, a stearic acid EO9 mol adduct, etc. are mentioned.

  Examples of the polyhydric alcohol type nonionic surfactant (B3-4) include EO and / or 2-8 polyhydric alcohols having 3 to 36 carbon atoms (such as glycerin, trimethylolpropane, pentaerythritol, sorbit and sorbitan). Or PO adducts, fatty acid esters of polyhydric alcohols and EO adducts thereof, sugar fatty acid esters, fatty acid alkanolamides (such as coconut oil fatty acid diethanolamide) and AO adducts thereof, and sorbitan tetraoleic acid Examples include ester EO adducts and sorbitan hexaoleate EO adducts.

  Examples of the cationic surfactant (B4) include an amine salt type cationic surfactant (B4-1) and a quaternary ammonium salt type cationic surfactant (B4-2).

  As amine salt type cationic surfactant (B4-1), laurylamine, stearylamine, triethanolamine monostearate ester, stearamide ethyldiethylamine, and condensate of stearic acid and aminoethylethanolamine are further condensed with urea. And acid neutralized products such as formic acid such as hardened beef tallow amine and rosin amine, acetic acid and hydrochloric acid.

  Examples of the quaternary ammonium salt type cationic surfactant (B4-2) include stearamide methylpyridinium chloride, lauryltrimethylammonium chloride, benzyllauryldimethylammonium chloride and cetylpyridinium bromide.

  As surfactant (B), from the viewpoint of secretion efficiency, carboxylate type amphoteric surfactant (B1-1), ether carboxylic acid (B2-1), sulfonate (B2-4), higher alcohol AO Adducts (B3-1) and polyhydric alcohol type nonionic surfactants (B3-4) are preferred, and more preferred are amidopropyl betaine laurate, betaine lauryldimethylaminoacetate, N-lauroyl-N′-carboxymethyl- N'-hydroxyethyl ethylenediamine sodium, coconut oil fatty acid amidopropyl betaine, lauric acid amidopropyl betaine, lauryl dimethylaminoacetic acid betaine, sodium cocaminopropionate, polyoxyethylene lauryl ether acetate sodium, polyoxyethylene tridecyl ether acetate sodium salt , De Sodium sill diphenyl ether disulfonic acid, polyoxyethylene alkyl ethers, polyoxyalkylene alkyl ethers and coconut oil fatty acid diethanolamide.

In the present invention, as the surfactant (B), the surfactant (B) may be used as it is, or mixed with water as necessary to obtain an aqueous diluent (aqueous solution or aqueous dispersion). Can be used.
The total concentration of the surfactant (B) in the aqueous dilution is appropriately selected depending on the target bacteria, the type of physiologically active substance, and the type of secretion method. From the viewpoint of secretion and handling properties of useful substances, Based on the weight of the aqueous diluent, it is preferably 0.1 to 99% by weight, more preferably 1 to 50% by weight.

  The amount (% by weight) of the surfactant (B) contained in the culture solution in the step (a) described later is appropriately selected depending on the target bacteria, the kind of useful substance produced and the kind of secretion method. From the viewpoint of secretion efficiency and difficulty of protein denaturation based on the weight of the culture solution, 0.0001 to 10 is preferable, 0.005 to 10 is more preferable, and 0.01 to 5 is still more preferable. It is.

  The surfactant (B) may be added later to the culture solution in which the bacteria are suspended, in addition to using the surfactant (B) by mixing it with the culture solution in advance. Mixing with the culture solution can be performed by adding the surfactant (B) to the culture solution at 4 ° C to 99 ° C and stirring with a stirring blade or a stirrer. When mixing afterwards, it can carry out by adding, stirring with a stirring blade etc.

  In using the surfactant (B), in addition to using the surfactant (B) alone, several types may be mixed.

The useful substance production method of the present invention comprises the following steps (a) and (b).
Step (a): A step of causing a useful substance to be secreted outside the cell by simultaneously presenting a culture solution for cultivating bacteria producing the useful substance and the surfactant (B).
Step (b): A step of separating bacteria from the culture solution and useful substances.

  The start time of the said process (a) is a time when both the bacteria currently culture | cultivated and surfactant (B) are contained in the culture solution. Moreover, a process (a) is complete | finished by the start of a process (b).

  In the extracellular secretion production method for useful substances of the present invention, the culture solution is a liquid containing components for the growth of bacteria.

  The culture solution contains water, a carbon source, a nitrogen source, and the like. As the carbon source, bacteria can synthesize ATP (adenosine triphosphate) and can be assimilated by metabolism, and include sugars such as glucose, lipids and proteins. Nitrogen sources are those that bacteria can use for biosynthesis of proteins and nucleic acids, and include proteins, amino acids, ammonia, urea, and the like.

The protein concentration in the culture solution in the step (a) can be easily prepared by adding protein to the culture solution and adjusting the amount thereof.
Proteins added to the culture solution include polypeptone, bactotryptone, lactalbumin, soybean flakes, yeast extract, meat extract, blood, serum, corn steep liquor, whey, peanut mill, cottonseed mill, casein, gelatin, fish meal and The protein which is these decomposition products is mentioned.

  As the protein added to the culture solution, polypeptone, bactotryptone, lactalbumin, meat extract, whey and casein are preferable, and lactalbumin, whey and casein are more preferable from the viewpoint of improving the productivity of useful substances.

  In the extracellular secretion production method of the useful substance of the present invention, the protein concentration in the culture medium in the step (a) is 15 to 500 g / L during a time of 10% or more of the time required for the step (a). The protein concentration is 15 to 500 g / L based on the volume of the culture solution, preferably 20 to 200 g / L, and more preferably 25 to 150 g / L from the viewpoint of increasing the production amount. When the protein concentration is less than 15 g / L, the recombinant protein production efficiency deteriorates. When the protein concentration exceeds 500 g / L, the growth or survival of bacteria is adversely affected.

  The protein concentration in the present invention is a value measured using BSA as a calibration curve using the BCA method.

  Of the time required for the step (a), the time during which the protein concentration is within the above range is 10% or more, preferably 50% to 100%, more preferably 80% to 100% from the viewpoint of increasing the production amount. %. When the time required for the step (a) is less than 10%, the production amount of the recombinant protein is reduced.

  The step (b) is a step of separating bacteria from the culture solution and useful substances. As a separation method, for example, a method of separating bacteria from a culture solution and useful substances using a continuous centrifuge or a membrane such as a holofiber or a filter press is generally used and can be used in the present invention. .

  In the useful substance manufacturing method of the present invention, steps (a) and (b) may be repeated alternately a plurality of times. When the steps (a) and (b) are alternately repeated a plurality of times, the culture in the step (a) is performed in any step (a) for 10% or more of the time required for the step (a). It is sufficient that the protein concentration in the liquid satisfies 15 to 500 g / L, and it is preferable to satisfy all the steps (a).

An example of a method for producing useful substances using bacteria is shown below.
(I) gene recombination (i-1) messenger RNA (mRNA) is isolated from cells expressing the target protein, single-stranded cDNA is synthesized from the mRNA, and then double-stranded DNA is synthesized. Alternatively, it is incorporated into a plasmid. Alternatively, useful genes on the genomic DNA are directly amplified by a method such as PCR (Polymerase Chain Reaction), and the DNA is incorporated into a phage or a plasmid.
(I-2) Transform a host with the obtained recombinant phage or plasmid, and after cultivation, target DNA by hybridization with a DNA probe encoding a part of the target protein gene, or immunoassay using an antibody A phage or plasmid containing is isolated.
(I-3) It can be produced by cutting out the desired cloned DNA from the recombinant phage DNA or plasmid, and ligating the cloned DNA or a part thereof downstream of the promoter in the expression vector. DNAs encoding a signal sequence for translocating the inner membrane (a signal sequence for expressing a target substance in the periplasmic space) can be linked simultaneously.

  Examples of the plasmid include pUC series such as pUC19, pET series such as pET-22b, pBAD series, and pBR322.

(Ii) Culture (ii-1) A bacterium for producing a useful substance is transformed with an expression vector and cultured. The culture is usually performed on an agar medium at 15 to 43 ° C. for 3 to 72 hours.
(Ii-2) Autoclave sterilization is performed for the culture solution used for culture at 121 ° C. for 20 minutes, and the recombinant bacteria cultured on the agar medium is inoculated therein to start main culture. The main culture is usually performed at 15 to 43 ° C. for 12 to 72 hours. In this step, the surfactant (B) is added. When the surfactant (B) is used from the beginning of the culture, a homogenized mixture of (B) and the culture solution is used as the culture solution. When (B) is used after the start of the culture, the surfactant (B) is added for a period of 5 to 100 hours by adding the surfactant (B) between immediately after the start of the culture and 72 hours after the start of the culture.
In the main culture, when (B) is used from the beginning of the culture, the main culture indicates the step (a). When (B) is used after the start of the culture, the process ( a).
In step (a), the protein concentration is measured. Sampling is performed every 0.5-12 hours from the time point when both the bacteria and the surfactant (B) are contained, and the protein concentration is measured. The graph is plotted with the protein concentration on the vertical axis and the time on the horizontal axis. Draw and check the percentage of time that the protein concentration is above. The protein concentration is prepared by adding protein or culture medium and adjusting the amount thereof.
In (ii-2), the concentration of bacteria is preferably 1 to 10 ¹³ cells / ml, more preferably 10 ² to 10 ¹¹ cells / ml.
In (ii-2), the usage-amount (weight%) of surfactant (B) is as above-mentioned.

(Iii) Purification (iii-1) Separation into bacteria, culture solution and useful substances by centrifugation, hollow fiber separation, filtration and the like.
(Iii-2) Useful substances and culture solutions are further subjected to precipitation treatment such as ethanol precipitation, ammonium sulfate precipitation and polyethylene glycol precipitation by repeating column treatments such as ion exchange column, gel filtration column, hydrophobic column, affinity column and ultra-violet column. As necessary, it is separated and purified into useful substances and culture solution.

  The bacteria isolated in (iii-1) can then be further cultured by returning them to the culture kettle and supplying a new culture solution. By further subjecting the culture solution and the like to the step (iii) and repeating the purification and culture, continuous production of useful substances can be performed.

  Examples of the filler used in the column chromatography in the separation / removal step of the useful substance (iii) include silica, dextran, agarose, cellulose, acrylamide, vinyl polymer, and the like, and commercially available products include Sephadex series and Sephacryl. Series, Sepharose series (above, Pharmacia), Bio-Gel series (Bio-Rad), etc. are available.

  Examples of the membrane in the above (iii) cell and useful substance separation / removal step include a hollow fiber type separation device and a flat membrane type membrane separation device. Commercially available products include CFP series such as CFP-2-E-55 (GE), UFP series such as UFP-10-E-65 (GE), MF series (Millipore), UF series (Millipore). It is available.

  The useful substance obtained by the production method of the present invention has higher purity than before. Moreover, since it is excellent in productivity, a high yield can be obtained.

  The present invention will be further described with reference to the following examples and comparative examples, but the present invention is not limited thereto.

<Production Example 1>
The subtilisin Carlsberg gene of Bacillus licheniformis was amplified by PCR using primers 1 and 2 (Table 1). The PCR amplified fragment was treated with restriction enzymes NcoI and BamHI, and then bound to the NcoI restriction enzyme site and the BamHI restriction enzyme site of the pET-22b plasmid (Novagen). Thereafter, transformation was performed to BL21 (DE3) E. coli strain (Novagen) to prepare E. coli (α) expressing protease.

<Production Example 2>
The bglC gene of Bacillus licheniformis was amplified by PCR using primers 3 and 4 (Table 1). The PCR amplified fragment was treated with restriction enzymes NcoI and BamHI, and then bound to the NcoI restriction enzyme site and the BamHI restriction enzyme site of the pET-22b plasmid (Novagen). Thereafter, transformation was performed to BL21 (DE3) E. coli strain (Novagen) to prepare E. coli (β) expressing cellulase.

<Production Example 3>
The lip gene of Thermomyces lanuginosus was amplified by PCR using primers 5 and 6 (Table 1). The PCR amplified fragment was treated with restriction enzymes NcoI and BamHI, and then bound to the NcoI restriction enzyme site and the BamHI restriction enzyme site of the pET-22b plasmid (Novagen). Then, it transformed into BL21 (DE3) E. coli strain (Novagen), and produced E. coli (γ) expressing lipase.

<Production Example 4>
The amyK gene of Bacillus licheniformis was amplified by PCR using primers 7 and 8 (Table 1). The PCR amplified fragment was treated with restriction enzymes NcoI and EcoRI, and then ligated to the NcoI restriction enzyme site and EcoRI restriction enzyme site of pET-22b plasmid (Novagen). Thereafter, transformation was performed to BL21 (DE3) E. coli strain (Novagen) to prepare E. coli (δ) expressing amylase.

<Comparative Examples 1-4>
E. coli (α) to (δ) were inoculated into 10 ml of LB culture solution (bactotryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L, ampicillin 100 mg / L) with a platinum loop and shaken at 37 ° C. overnight. Culture was performed. This culture solution was inoculated into 200 ml of a TB culture solution (Difco) containing 100 mg / L ampicillin and cultured at 37 ° C. When the turbidity of the culture solution becomes 2.0, IPTG is added so as to be 0.1 mM, and polyoxyethylene lauryl ether acetate sodium salt (Sanyo Kasei Kogyo Co., Ltd.) becomes 0.3% by weight. ), Trade name “Bulite LCA-25N”) was added. Thereafter, the culture is further continued, 15 ml is sampled every hour, the supernatant is collected by centrifugation, and the amount of the produced recombinant protein is quantified by SDS-PAGE, and the protein concentration in the culture solution Was quantified by the BCA method (Micro BCA Protein Assay Kit (PIERCE)). The results of quantifying the produced protein were 1.00 as the quantitative value of Comparative Examples 1 to 4, and the results of Examples 1 to 10 were expressed as relative values based on the quantitative values of Comparative Examples 1 to 4. The results are summarized in Tables 2-4.

<Examples 1-3>
Comparative Example 1 was cultured in the same manner as Comparative Example 1 except that lactalbumin was added to the TB culture solution before inoculating the TB culture solution with E. coli (α) cultured overnight in the LB medium. Evaluation was performed using the same method as in Example 1. The results of the relative values based on the quantitative values of the protein concentration and the amount of protease in Comparative Example 1 and Comparative Example 1 are summarized in Table 2.

<Example 4>
Comparative Example 1 is the same as Comparative Example 1 except that meat extract (manufactured by Wako Pure Chemical Industries, Ltd.) was added to the TB culture solution before inoculating E. coli (α) cultured overnight in the LB medium into the TB culture solution. The cells were cultured in the same manner and evaluated using the same method as in Comparative Example 1. The results of the relative values based on the quantitative values of the protein concentration and the amount of protease in Comparative Example 1 and Comparative Example 1 are summarized in Table 2.

<Example 5>
In Comparative Example 1, the same procedure as in Comparative Example 1 was conducted except that polypeptone (manufactured by Nippon Pharmaceutical Co., Ltd.) was added to the TB culture solution before inoculating E. coli (α) cultured overnight in the LB medium. The cells were cultured and evaluated using the same method as in Comparative Example 1. The results of the relative values based on the quantitative values of the protein concentration and the amount of protease in Comparative Example 1 and Comparative Example 1 are summarized in Table 2.

<Example 6>
Comparative Example 1 and Comparative Example 1 except that soybean protein (manufactured by Wako Pure Chemical Industries, Ltd.) was added to the TB culture solution before inoculating E. coli (α) cultured overnight in the LB medium into the TB culture solution. The cells were cultured in the same manner and evaluated using the same method as in Comparative Example 1. The results of the relative values based on the quantitative values of the protein concentration and the amount of protease in Comparative Example 1 and Comparative Example 1 are summarized in Table 2.

<Examples 7 to 8>
Comparative Example 2 is the same as Comparative Example 2 except that lactalbumin (manufactured by Wako Pure Chemical Industries, Ltd.) was added to the TB culture solution before inoculating E. coli (β) cultured overnight in the LB medium into the TB culture solution. The cells were cultured in the same manner and evaluated using the same method as in Comparative Example 2. Table 3 summarizes the results of the relative values based on the quantitative values of the protein concentration and the amount of cellulase in Comparative Example 2 and those of Comparative Example 2.

<Example 9>
In Comparative Example 3, culture was performed in the same manner as in Comparative Example 3 except that lactalbumin was added to the TB culture solution before inoculating E. coli (γ) cultured overnight in the LB medium in the TB culture solution. Evaluation was performed using the same method as in Example 3. Table 4 summarizes the results of relative values based on the quantitative values of the protein concentration and the amount of lipase in Comparative Example 3 with respect to Comparative Example 3.

<Example 10>
In Comparative Example 4, culturing was carried out in the same manner as in Comparative Example 4 except that lactalbumin was added to the TB culture solution before inoculating E. coli (δ) cultured overnight in the LB medium into the TB culture solution. Evaluation was performed using the same method as in Example 4. Table 5 summarizes the results of relative values based on the quantitative values of the protein concentration and the amount of amylase in Comparative Example 4 and those of Comparative Example 4.

<Production Example 5>
The pET-22b plasmid (Novagen) was transformed into BL21 (DE3) E. coli strain (Novagen) to produce E. coli (ε) expressing the peptide.

<Comparative Example 5>
Escherichia coli (ε) was inoculated into 10 ml of LB culture solution (bactotryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L, ampicillin 100 mg / L) with platinum ears and cultured overnight at 37 ° C. with shaking. It was. This culture solution was inoculated into 200 ml of a TB culture solution (Difco) containing 100 mg / L ampicillin and cultured at 37 ° C. When the turbidity of the culture solution reached 2.0, IPTG was added so as to be 0.1 mM, and Triton X-100 was added so as to be 0.3% by weight. Thereafter, the culture is further continued, sampling is performed at 15 ml intervals every hour, the supernatant is collected by centrifugation, and the amount of the produced peptide is quantified using an anti-His tag antibody by Western blotting, followed by culture. The protein concentration in the liquid was quantified by the BCA method (Micro BCA Protein Assay Kit (PIERCE)). As a result of quantifying the produced peptide, the quantitative value of Comparative Example 5 was set to 1.00, and the result of Example 11 was shown as a relative value based on the quantitative value of Comparative Example 5. The results are summarized in Table 6.

<Example 11>
The procedure was the same as in Example 1 except that the collected E. coli (ε) was used. Relative values based on the quantitative values in Comparative Example 5 were calculated, and the results are summarized in Table 6.

<Comparative Example 6>
10 ml of the overnight culture solution of E. coli (β) obtained in Production Example 2 was prepared, and 250 ml culture solution (TB culture solution (Difco), 0.7 wt% ammonium sulfate, 0.05 wt% diammonium citrate, 1 mM sulfate) Inoculated with magnesium) and cultured using a 1 L microorganism culture apparatus (Able) while maintaining the pH at 7.0 and 37 ° C. Three hours after the start of culture, coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine (trade name “Levon 2000” manufactured by Sanyo Chemical Industries, Ltd.) was added so that 1M IPTG was 0.75 ml and 0.3% by weight. . 8 hours after the start of culture, 50% glycerin was added dropwise at a rate of 2 ml / hour, 15 ml was sampled every 12 hours, the supernatant was collected by centrifugation, and the amount of cellulase produced was 60 hours. Samples collected in the above were analyzed by SDS-PAGE to quantify the bands, and the protein concentration in the culture was determined by the BCA method (Micro BCA Protein Assay Kit (PIERCE)). The result of quantifying the produced cellulase was 1.00 as the quantitative value of Comparative Example 6, and the results of Examples 12 and 13 were expressed as relative values based on the quantitative value of Comparative Example 6. The results are summarized in Table 7.
<Example 12 and Example 13>
Except that lactalbumin was added to the culture solution in the microorganism culture apparatus from the beginning of the culture, the same procedure as in Comparative Example 6 was performed, and the relative values based on the quantitative values in Comparative Example 6 were calculated and summarized in Table 7. .

From Tables 2 to 6, Examples 1 to 11 using the method of the present invention have a relative value larger than 1 based on the quantitative value of the useful substance produced in the corresponding comparative example. It can be seen that the production amount of useful substances increases by keeping the protein concentration of 15 g / L or more.
Similarly, in the case where the culture time shown in Table 7 is long (60 hours), Examples 12 and 13 using the method of the present invention are comparative examples by setting the protein concentration in the culture solution to 15 g / L or more. It turns out that the production amount of a useful substance increases rather than six. Furthermore, it can be seen that the production amount of useful substances increases when the protein concentration in the culture solution is kept at 15 g / L or more for a long time.

  The method for producing a useful substance of the present invention can be used when producing a useful substance such as a protein. Examples of proteins include enzymes, hormone proteins, antibodies, vaccines and peptides. It can also be used as an extraction reagent for bacterial periplasmic fractions. Furthermore, it is possible to produce protease, cellulase, lipase, amylase, mannanase, glucose oxidase and the like by using the method of the present invention, detergent use, textile processing use, paper processing use, food use, biofuel production use, enzyme It can be used for conversion use, feed use, cosmetic use, genetic engineering use, diagnostic use, pharmaceutical use, and the like.

Claims (3)

A method for extracellular secretion production of a useful substance comprising the following steps (a) and (b), wherein the protein concentration in the culture solution in step (a) is 10% or more of the time required for step (a): The useful substance manufacturing method whose is 15-500 g / L.
Step (a): A step of causing a useful substance to be secreted outside the cell by simultaneously presenting a culture solution for cultivating bacteria producing the useful substance and the surfactant (B).
Step (b): A step of separating bacteria from the culture solution and useful substances. The method for producing a useful substance according to claim 1, wherein the useful substance is a peptide or a protein. The method for producing a useful substance according to claim 1 or 2, wherein the bacterium is Escherichia coli.